CClinicalTrials.gg
RecruitingNCT05822258DetectFoGUpdated Oct 9, 2024

DetectFoG : Detection of Gait Freezing Episodes in Parkinsonian Patients Using Inertial Measurement Units

An interventional study of Walk under 3 conditions (normal, physical tasks, verbal tasks) in Parkinson Disease, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Feb 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Parkinson's disease is the second most common neurodegenerative disease in the world. One of these manifestations is the freezing of gait (FOG) which affects 50 to 80% of Parkinsonian patients. It is defined as a brief and episodic absence or marked reduction in the forward progression of the feet despite the intention to walk. FOG is one of the most disabling symptoms causing a greater risk of falling and a loss of autonomy for these patients. This symptom is little or not dopamine-sensitive and little improved by surgery (deep brain stimulation).

Although this symptom is common and debilitating, it is difficult to assess clinically. The objective assessment of the presence and severity of FOG episodes can be done with tests such as the New-Freezing of Gait Questionnaire (N-FOGQ) with however limitations. Indeed, this filmed examination is scored a posteriori and the accumulation of the administration times which makes it difficult to use in routine clinical practice. To overcome these limitations, the use of a diary completed by the patient himself is a simple alternative to assess this symptom, but studies show that patients abandon this practice in the long term and that it is not used by patients with cognitive impairment.

Recent advances in miniaturization have made it possible to create light and compact sensors to assess these events objectively. Inertial measurement units have been widely used in the literature to detect FOG episodes. The choice of the detection algorithms are a major issue in the scientific community. To date, due to the heterogeneity of the protocols, no method is currently required as a reference.

The objective is to evaluate the accuracy of a new algorithm to detect the number of FOG episodes in Parkinsonian patients. This evaluation will be done on the freeze-inducing walking path.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Freezing of Gait
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 20 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Rennes University Hospital is the lead sponsor of 440 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient over 18 years old
  • With Parkinson's disease according to the United Kingdom Brain Bank criteria
  • Presenting episodes of freezing of gait assessed on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS II - question 13 with a score between 1 and 3 in order to have a patient walking without technical assistance) produced by the neurologist
  • Able to walk 30 meters independently
  • Affiliated to a social security scheme or beneficiary of such a scheme
  • Having signed a free and informed consent in writing

Exclusion criteria

Exclusion Criteria:

  • Montreal Cognitive Assessment (MOCA) \< 20/30
  • Other neurological or orthopedic history that interferes with walking
  • Pregnant, parturient or breastfeeding women
  • Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
  • Persons undergoing psychiatric care, persons admitted to a health or social establishment for purposes other than research
  • Minors
  • Persons unable to express their consent
  • Simultaneous participation in another research related to balance and/or walking
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Freezing of Gait

    Each patient will have 2 visits : * First visit in the "ON" state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms. * A second visit in the "OFF" phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions: * Normal condition without additional physical and verbal tasks * Condition with added physical tasks: The physical task of holding a ball in the center of a tray. * Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter. Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions (normal, double physical task and double verbal task). A rest period will be observed.

    Other: Walk under 3 conditions (normal, physical tasks, verbal tasks)

Interventions

  • OtherWalk under 3 conditions (normal, physical tasks, verbal tasks)

    Each patient will have 2 visits : * First visit in the "ON" state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms. * A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the "OFF" phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions: * Normal condition without addition of additional physical and verbal tasks * Condition with added physical tasks: The physical task of holding a ball in the center of a tray * Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter. Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions.

06

What researchers measure

Primary outcomes

  1. Precision

    Every second of the course will be analyzed to define : * the "true positive" time: FOG detected by the algorithm and the two experts * True negative" time: FOG detected by neither the algorithm nor the two experts * False positive" time: FOG detected by the algorithm but not by the two experts * False negative" time: FOG not detected by the algorithm but detected by both experts For each course completed, accuracy will then be calculated as the ratio between the sum of the time spent in "true positive" and "true negative" divided by the time taken to complete the course. The average of these ratios is then calculated to estimate the accuracy of all runs performed, i.e. taking into account all repetitions performed by patients, regardless of run type and ON/OFF status.

    Time frame: Through study completion, an average of 15+/-7 days

Secondary outcomes

  1. Sensitivity

    Sensitivity will be calculated as the ratio of time spent in "true positive" divided by the sum of time spent in "true positive" and "false negative". These ratios will then be averaged to estimate accuracy over all the runs performed, i.e. taking into account all the repetitions performed by patients, regardless of run type and ON/OFF status.

    Time frame: Through study completion, an average of 15+/-7 days

  2. Specificity

    Specificity will be calculated as the ratio of time spent in "true negative" divided by the sum of time spent in "true negative" and "false positive". These ratios will then be averaged to estimate accuracy over all the runs performed, i.e. taking into account all the repetitions performed by patients, regardless of run type and ON/OFF status.

    Time frame: Through study completion, an average of 15+/-7 days

  3. Positive predictive value (PPV)

    The positive predictive value will be calculated as the ratio of time spent in "true positive" divided by the sum of time spent in "true positive" and "false positive". The average of these ratios will then be calculated to estimate the accuracy over all the runs performed, i.e. taking into account all the repetitions performed by patients, regardless of run type and ON/OFF status.

    Time frame: Through study completion, an average of 15+/-7 days

  4. Negative predictive value (NPV)

    The negative predictive value will be calculated as the ratio of time spent in "true negative" divided by the sum of time spent in "true negative" and "false negative". The average of these ratios will then be calculated to estimate the accuracy over all the runs performed, i.e. taking into account all the repetitions performed by patients, regardless of run type and ON/OFF status.

    Time frame: Through study completion, an average of 15+/-7 days

  5. Time difference

    The time difference between the start of the episode detected by the experts and that detected with the

    Time frame: Through study completion, an average of 15+/-7 days

Other outcomes

  1. Ability to generate FOG episodes between different pathway modalities

    The ability to generate FOG episodes between different pathway modalities will be analyzed by comparing, for each pathway type, the percentage of time in FOG assessed by the experts using a mixed model (fixed effect on patients and random effect on pathway type).

    Time frame: Through study completion, an average of 15+/-7 days

  2. Ability to generate FOG episodes according to medical conditions (ON/OFF)

    The ability to generate FOG episodes according to medical conditions (ON/OFF) will be analyzed by comparing for each type of pathway the percentage of time in FOG assessed by experts using a mixed model (fixed effect on patients and random effect on ON/OFF status).

    Time frame: Through study completion, an average of 15+/-7 days

  3. Algorithm performance according to pathway

    Algorithm performance (accuracy, sensitivity, specificity, PPV, NPV) according to pathway type will be analyzed using a mixed model (fixed effect on patients and random effect on pathway type).

    Time frame: Through study completion, an average of 15+/-7 days

  4. Algorithm performance according to medical conditions (ON/OFF)

    Algorithm performance (accuracy, sensitivity, specificity, PPV, NPV) according to medical conditions (ON/OFF) will be analyzed using a mixed model (fixed effect on patients and random effect on ON/OFF status).

    Time frame: Through study completion, an average of 15+/-7 days

07

Study locations

1 of 1 sites recruiting
  • Rennes University Hospital
    Rennes, Brittany 35000, France
    • Karim Jamal, MD · Contact · karim.jamal@chu-rennes.fr · 02 99 28 90 51
    • karim.jamal@chu-rennes.fr, MD · Contact
    • Karim Jamal, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05822258
Lead sponsor
Rennes University Hospital
Responsible party
Sponsor
First posted
Apr 20, 2023
Start date
Jan 8, 2024
Primary completion
Feb 8, 2026 (estimated)
Completion
Aug 8, 2026 (estimated)
Last update
Oct 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion